Richard Fisher, PhD
Chief Scientific Officer
Richard Fisher has been the chief scientific officer at Proclara since 2008, where he co-invented the company’s GAIM technology. He has more than 35 years of experience in the biotech industry leading research and development teams. Prior to joining Proclara, he served as the chief scientific officer of Intranasal Therapeutics (now Ikano Therapeutics), a venture-backed specialty pharmaceutical company, and led the development of intranasal midazolam for treating epilepsy, a project later acquired by Upsher-Smith. Before that, Fisher worked at GlycoFi, a glycoprotein engineering technology start-up, as the senior vice president of research and product development, where he led product translational research and managed multiple pharma collaborations until the company was acquired by Merck in 2006. Previously, he was the vice president of research and discovery at CytoMed and led several inflammatory drug discovery programs, which were acquired by UCB Pharma in 1998. After CytoMed’s acquisition, he helped create a 100-person small molecule research and discovery site in Cambridge, which discovered the brain target of the epilepsy drug, Keppra®. This discovery led to further discoveries of next generation epilepsy drugs. Fisher began his career as one of the first U.S.-based employees at Biogen, where he held positions of increasing responsibility, including director of molecular biology, AIDS program leader, and director of science and technology. Fisher earned his Bachelor of Arts in Zoology and his doctorate in Microbiology/Molecular Genetics, both from the University of Iowa. He completed an American Cancer Society postdoctoral fellowship at the University of Chicago.